The Next Step in Pain Management Research
Our Clinical Research
In our phase 3 randomised double blind controlled clinical trial (NCT01528332) conducted in three outpatient pain centres in Germany, 171 patients with chronic back pain were treated with our patented blue light or a Control stimulation. The results showed that compared to the control group, patients treated with blue light for over 2 weeks had a statistically significant decrease in their pain (p<0.05, two-sided). No substantial differences in safety outcomes were seen between groups treated with the Active and the Control device (data on file).
These data were confirmed in an observational study that included 633 patients treated with blue light in 77 outpatient pain centres in Germany. After 2 weeks of treatment, there was a statistically significant pain reduction by an average of 28% (p<0.001). In addition, there was a significant reduction in pain-related restrictions in daily functioning (p<0.001) paralleled by a significant improvement in quality-of-life.
Advancing the science
What Is the Next ANALGESIX® Clinical Trial?
Heat2Move is preparing the launch of a new clinical trial in Germany and the Netherlands. This study will investigate the efficacy and safety of AnalgesiX® system in chronic low back pain and aims to demonstrate the benefice of our innovation on multiples patient reported outcomes that go beyond pain intensity reduction only.
Stay tuned for more detailed information on this clinical trial.
Guiding Scientific Excellence
Meet Our Clinical Trial Expert Committee
Prof. Albert Dahan
A distinguished figure in anaesthesiology, Prof. Dahan leads the Anaesthesia & Pain Research Unit, focusing on outcome-driven research in anaesthesia and pain medicine.
He is the founder and the head the Anesthesia & Pain Research Unit, a non-profit organisation that performs outcomes-research in anesthesia and pain medicine.
Finally, he is board member of PainLess.
Prof. Dr. Bart Morlion, MD, PhD, DEAA, EDPM
Professor Bart Morlion trained as an anesthesiologist but works full time in pain medicine. In addition to his role as a Director at the Leuven Centre for Algology & Pain Management, he is also a clinical professor at the University of Leuven. Prof. Morlion is past president of the European Pain Federation EFIC (2017-2020) and past president of the Belgian Pain Society (2006-2012). He is program director of the Belgian Interuniversity Postgraduate Studies in Algology and is also an active member of several committees in international scientific societies. Prof. Bart Morlion is the author of numerous publications on the management of pain.
Prof. Ralf Baron, MD, PhD
Ralf Baron Professor Dr med FFPMCAI is Head of the Division of Neurological Pain Research and Therapy at the Department of Neurology, Christian-Albrechts-Universitaet Kiel, in Germany. Professor Baron served at the head of many prestigious pain institutions and committees such as the International Association for the Study of Pain (IASP). Professor Baron published more than 400 publications and has been the recipient of the German Pain Award, the Heinrich-Pette-Award of the German Neurological Society and the Sertürner-Award.
Interested in Our Upcoming Clinical Trial?
Join us on the forefront of pain management research. Sign up now to receive the latest updates and be part of the breakthrough journey in chronic pain treatment.